Singapore: Healthcare firm CordLife invests $5.9m in CellResearch Corporation

Visual from the Cordlife Singapore website. September 2015

Healthcare firm Cordlife Group said today it has invested an additional S$8.4 million (US$5.9 million) in its strategic alliance with CellResearch Corporation (CRC).

Funded by internal resources, the strategic alliance between Cordlife and CRC was incepted in 2010 to provide an umbilical cord lining (UCL) banking service leveraging on CRC’s technology for harvesting stem cells from the amniotic membrane of the umbilical cord.

Gavin Tan, CEO of CRC observed: “Since 2010, our strategic alliance with Cordlife has grown from strength to strength. We are delighted with this latest development as it narrows the gap between the banking of umbilical cord lining stem cells and their broader therapeutic uses.”

Tan added, “Together with Cordlife and our clinical development partners, we are accelerating the development of the Global Cord Registry and CRC’s stem cell technology to benefit patients, customers and the broader medical community.”

According to Cordlife, the nature of the investment is a subscription for a Class A redeemable convertible note (RCN) maturing three years from the issue date in the principal amount of S$4.2 million (US$2.95 million) from CRC. For this note, the yielding interest is at a rate of three month SIBOR plus 7 per cent per annum, payable annually in arrears.

Also Read: Exclusive: Malaysia’s BookDoc courting HK, Indonesia, Thai healthcare groups for pre-Series A

India: Healthcare focussed PE fund Quadria to pick 20% in Concord Biotech

Robust Plan withdraws offer for Cordlife’s China assets

In addition, Cordlife will purchase 4,167,858 ordinary shares in CRC for a consideration of S$4.2 million. An adjustment mechanism will enable Cordlife to, among others, either receive additional ordinary shares in CRC or sell the shares back to CRC shareholders at a price of the consideration plus 7 per cent of the consideration compounded over 3 years. This will occur if a net profit target is not met for the year ending 31 December 2018.

The proceeds from the RCN will be primarily used to accelerate the clinical development of the advanced wound healing technology, significant enhancing the value proposition of Cordlife’s UCL banking service in existing markets across the region. Currently, Cordlife caters to customers from India, Hong Kong, Singapore, Thailand, Philippines, Malaysia, Indonesia and China.

This follows CRC establishing a research partnership with the University of Colorado School of Medicine and ClinImmune Labs in June 2015. The objective of this is to embark on US FDA approved trials for the treatment of diabetic wounds using UCL stem cells.

Jeremy Yee, executive director and CEO of Cordlife, said, “This investment not only aligns the strategic interest between Cordlife and CRC, but also significantly enhances Cordlife’s clinical and quality assurance capacity as we are able to leverage on reputable research institutions and top-notch research facilities.”

Yee also noted that it would position Cordlife to contribute to the clinical development of CRC’s wound healing technology, as this would enable further validation and strengthening of Cordlife’s core business activities, as well as capitalise on growth opportunities in the cord blood and cord lining banking market.

Also Read: Singapore: Cordlife hikes stake in StemLife to over 50%, makes it subsidiary

MY Dealbook: MRCB places office tower into MQREIT; CordLife ups stake in StemLife

SG Dealbook: Cordlife considers M&A, KS Energy acquires OOE in $1.63m deal

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.